Please try another search
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase III clinical trial. It also develops influenza, breast cancer, and malaria vaccines. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for application as research tools or diagnostics. It has a collaboration agreement with Evaxion Biotech A/S for the development of a novel cytomegalovirus (CMV) vaccine candidate. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Martin Roland Jensen | 63 | 2010 | Chairman of the Board |
Jakob Knudsen | 55 | 2017 | Independent Director |
Karin Garre | 66 | 2021 | Independent Director |
Sara Sande | 48 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review